SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
+3.76%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$151M
AUM Growth
+$151M
(+18%)
Cap. Flow
+$26.9M
Cap. Flow
% of AUM
17.79%
Top 10 Holdings %
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$2.19M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$2.16M |
| 3 |
Replimune Group
REPL
|
$2.15M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$2.15M |
| 5 |
Solid Biosciences
SLDB
|
$2.05M |
Top Sells
| 1 |
Medtronic
MDT
|
$2.14M |
| 2 |
Gilead Sciences
GILD
|
$1.37M |
| 3 |
Tenet Healthcare
THC
|
$1.21M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$1.12M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$994K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LENZ
1
LENZ Therapeutics
LENZ
$1.1B
| $28.6M | 18.91% | 977,245 | – | – |
|
2
Eli Lilly
LLY
$657B
| $7M | 4.62% | 8,976 -440 | -5% | -$343K |
|
3
UnitedHealth
UNH
$281B
| $5.22M | 3.45% | 16,745 +3,850 | +30% | +$1.2M |
|
4
Mineralys Therapeutics
MLYS
$1.03B
| $5.17M | 3.42% | 382,415 +11,902 | +3% | +$161K |
|
|
CTNM
5
Contineum Therapeutics
CTNM
$293M
| $3.18M | 2.1% | 800,787 | – | – |
|
6
Amgen
AMGN
$155B
| $3.15M | 2.08% | 11,270 +885 | +9% | +$247K |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $3.09M | 2.04% | 6,945 +2,220 | +47% | +$988K |
|
8
Johnson & Johnson
JNJ
$427B
| $2.95M | 1.95% | 19,300 -2,500 | -11% | -$382K |
|
9
Intuitive Surgical
ISRG
$170B
| $2.85M | 1.88% | 5,250 | – | – |
|
10
AbbVie
ABBV
$372B
| $2.75M | 1.81% | 14,800 | – | – |
|
|
11
Oric Pharmaceuticals
ORIC
$994M
| $2.35M | 1.55% | 231,485 +211,485 | +1,057% | +$2.15M |
|
12
Boston Scientific
BSX
$156B
| $2.27M | 1.5% | 21,126 -3,100 | -13% | -$333K |
|
13
argenx
ARGX
$43.6B
| $2.25M | 1.49% | 4,085 +982 | +32% | +$541K |
|
|
MBX
14
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $2.19M | 1.45% | +191,825 | New | +$2.19M |
|
|
15
Gilead Sciences
GILD
$140B
| $2.18M | 1.44% | 19,690 -12,330 | -39% | -$1.37M |
|
|
PVLA
16
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $2.16M | 1.42% | +95,615 | New | +$2.16M |
|
|
17
Replimune Group
REPL
$422M
| $2.15M | 1.42% | +231,650 | New | +$2.15M |
|
18
Arcus Biosciences
RCUS
$1.13B
| $2.09M | 1.38% | 257,270 +230,400 | +857% | +$1.88M |
|
19
Danaher
DHR
$147B
| $2.09M | 1.38% | 10,575 | – | – |
|
20
Abbott
ABT
$231B
| $2.07M | 1.36% | 15,198 -3,500 | -19% | -$476K |
|
|
21
Solid Biosciences
SLDB
$427M
| $2.05M | 1.36% | +421,580 | New | +$2.05M |
|
|
RAPP
22
Rapport Therapeutics
RAPP
$643M
| $2.05M | 1.35% | +179,860 | New | +$2.05M |
|
|
ZBIO
23
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $2.04M | 1.35% | +210,625 | New | +$2.04M |
|
24
Ventyx Biosciences
VTYX
$171M
| $1.99M | 1.32% | +931,620 | New | +$1.99M |
|
|
TECX
25
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $1.97M | 1.3% | +98,970 | New | +$1.97M |
|